CDK9 and mTOR: trading places

被引：3

作者：

Borden, Katherine L. B. ^{[1
]}

机构：

[1] Univ Montreal, Montreal, PQ, Canada

来源：

BLOOD | 2019年 / 133卷 / 11期

关键词：

CLINICAL-TRIAL;

D O I：

10.1182/blood-2019-01-895086

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Beauchamp et al1 reveal that the kinase CDK9, typically associated with transcriptional elongation, 2 directly modulates translation through coopting components of the major translational regulatory complex mammalian target of rapamycin (mTOR). 3,4 These studies represent a major shift fromthe current paradigm; specifically, this work demonstrates that other kinases can coopt mTOR cofactors in order to modulate not only translation but also transcription as well as positioning CDK9 as an RNA processing cofactor.

引用

收藏

页码：1167 / 1168

页数：2

相关论文

共 10 条

[1] Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin [J].

Assouline, Sarit ;

Culjkovic, Biljana ;

Cocolakis, Eftihia ;

Rousseau, Caroline ;

Beslu, Nathalie ;

Amri, Abdellatif ;

Caplan, Stephen ;

Leber, Brian ;

Roy, Denis-Claude ;

Miller, Wilson H., Jr. ;

Borden, Katherine L. B. .

BLOOD, 2009, 114 (02) :257-260

[2] Identification and targeting of novel CDK9 complexes in acute myeloid leukemia [J].

Beauchamp, Elspeth M. ;

Abedin, Sameem M. ;

Radecki, Sara G. ;

Fischietti, Mariafausta ;

Arslan, Ahmet Dirim ;

Blyth, Gavin T. ;

Yang, Angela ;

Lantz, Connor ;

Nelson, Alissa ;

Goo, Young Ah ;

Akpan, Imo ;

Eklund, Elizabeth A. ;

Frankfurt, Olga ;

Fish, Eleanor N. ;

Thomas, Paul M. ;

Altman, Jessica K. ;

Platanias, Leonidas C. .

BLOOD, 2019, 133 (11) :1171-1185

[3] Regulatory Potential of the RNA Processing Machinery: Implications for Human Disease [J].

Carey, Kirstyn T. ;

Wickramasinghe, Vihandha O. .

TRENDS IN GENETICS, 2018, 34 (04) :279-290

[4] Aiding and abetting cancer: mRNA export and the nuclear pore [J].

Culjkovic-Kraljacic, Biljana ;

Borden, Katherine L. B. .

TRENDS IN CELL BIOLOGY, 2013, 23 (07) :328-335

[5] Targeting the mTOR Pathway in Leukemia [J].

Dinner, Shira ;

Platanias, Leonidas C. .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2016, 117 (08) :1745-1752

[6] Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1 [J].

Guertin, David A. ;

Stevens, Deanna M. ;

Thoreen, Carson C. ;

Burds, Aurora A. ;

Kalaany, Nada Y. ;

Moffat, Jason ;

Brown, Michael ;

Fitzgerald, Kevin J. ;

Sabatini, David M. .

DEVELOPMENTAL CELL, 2006, 11 (06) :859-871

[7] Eukaryotic mRNPs may represent posttranscriptional operons [J].

Keene, JD ;

Tenenbaum, SA .

MOLECULAR CELL, 2002, 9 (06) :1161-1167

[8] Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target [J].

Krystof, Vladimir ;

Baumli, Sonja ;

Fuerst, Robert .

CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (20) :2883-2890

[9] A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies [J].

Rizzieri, David A. ;

Feldman, Eric ;

DiPersio, John F. ;

Gabrail, Nashat ;

Stock, Wendy ;

Strair, Roger ;

Rivera, Victor M. ;

Albitar, Maher ;

Bedrosian, Camille L. ;

Giles, Francis J. .

CLINICAL CANCER RESEARCH, 2008, 14 (09) :2756-2762

[10]

Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]